Yannick Vanloubbeeck | Head of Immunology

Yannick Vanloubbeeck, Head of Immunology, GSK

Yannick Vanloubbeeck (DVM, PhD) is Head of Immunology at GSK Vaccines R&D, based in Belgium. He has joined GSK Vaccines in 2006 to lead the preclinical development of vaccine candidates against diseases of the developing world, including malaria & tuberculosis. In his current role he is responsible for the immunology evaluation of vaccine candidates at discovery/early stage of development as well as the preclinical evaluation of adjuvants & the study of their mode of action.


WVIC/WAC Day 2 - Nov 30 @ 09:00

Global Health Goals – can we get back on track?

  • How has the pandemic affected the status of the epidemics of tuberculosis, malaria and neglected tropical diseases?
  • Silver linings – new investments in immunization infrastructure – understanding of barriers and opportunities in promoting vaccination within communities and countries. How do we try to capitalize on some of the new pathways generated because of covid?
  • How will malaria vaccines be implemented? How does this vaccine need to be promoted differently to previous vaccines? How to communicate value of vaccines in burdened communities. Integrated strategy required.
  • TB vaccines how are we moving forward? Next steps for TB vaccines.
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard


For sponsorship and exhibition opportunities:
Thomas Hall